Mirzotamab clezutoclax
Mirzotamab clezutoclax (ABBV-155) is a first-in-class antibody-drug conjugate (ADC) with three components: an anti-B7-H3 monoclonal antibody, and BCL2L1 (BCL-XL) inhibitor Clezutoclaxum (HY-137774) . Mirzotamab clezutoclax can be used for the study of relapsed and/or refractory (R/R) solid tumors[1].
Product Specifications
CAS Number
[2229859-12-3]
Product Name Alternative
ABBV-155
UNSPSC
12352100
Target
Antibody-Drug Conjugates (ADCs) ; Bcl-2 Family; CD276/B7-H3
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
[Mirzotamabclezutoclax]
References & Citations
[1]Tolcher A W, et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. 2021.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
Bcl-xL
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1320206-01 0.02 mg (E-Coli)
Recombinant Xanthomonas oryzae pv. oryzae 8-amino-7-oxononanoate synthase (bioF)
Ask
View Details 
MBS1320206-02 0.02 mg (Yeast)
Recombinant Xanthomonas oryzae pv. oryzae 8-amino-7-oxononanoate synthase (bioF)
Ask
View Details 
MBS1320206-03 0.1 mg (E-Coli)
Recombinant Xanthomonas oryzae pv. oryzae 8-amino-7-oxononanoate synthase (bioF)
Ask
View Details